z-logo
Premium
Ubiquitin‐dependent regulation of MEKK 2/3‐ MEK 5‐ ERK 5 signaling module by XIAP and c IAP 1
Author(s) -
Takeda ArmelleNatsuo,
OberoiKhanuja Tripat Kaur,
Glatz Gabor,
Schulenburg Katharina,
Scholz RolfPeter,
Carpy Alejandro,
Macek Boris,
Remenyi Attila,
Rajalingam Krishnaraj
Publication year - 2014
Publication title -
the embo journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.484
H-Index - 392
eISSN - 1460-2075
pISSN - 0261-4189
DOI - 10.15252/embj.201487808
Subject(s) - biology , mapk/erk pathway , mek inhibitor , microbiology and biotechnology , kinase
Mitogen‐activated protein kinases ( MAPK s) are highly conserved protein kinase modules, and they control fundamental cellular processes. While the activation of MAPK s has been well studied, little is known on the mechanisms driving their inactivation. Here we uncover a role for ubiquitination in the inactivation of a MAPK module. Extracellular‐signal‐regulated kinase 5 ( ERK 5) is a unique, conserved member of the MAPK family and is activated in response to various stimuli through a three‐tier cascade constituting MEK 5 and MEKK 2/3. We reveal an unexpected role for Inhibitors of Apoptosis Proteins ( IAP s) in the inactivation of ERK 5 pathway in a bimodal manner involving direct interaction and ubiquitination. XIAP directly interacts with MEKK 2/3 and competes with PB 1 domain‐mediated binding to MEK 5. XIAP and c IAP 1 conjugate predominantly K63‐linked ubiquitin chains to MEKK 2 and MEKK 3 which directly impede MEK 5– ERK 5 interaction in a trimeric complex leading to ERK 5 inactivation. Consistently, loss of XIAP or c IAP 1 by various strategies leads to hyperactivation of ERK 5 in normal and tumorigenic cells. Loss of XIAP promotes differentiation of human primary skeletal myoblasts to myocytes in a MEKK 2/3‐ ERK 5‐dependent manner. Our results reveal a novel, obligatory role for IAP s and ubiquitination in the physical and functional disassembly of ERK 5‐ MAPK module and human muscle cell differentiation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here